ASX RELEASE | OSTEOPORE LIMITED

OSTEOPORE RECEIVES CE MARK FOR EXPANDED PRODUCT VARIANTS AND SHELF LIFE

Highlights:

- *CE Mark extended to include 7 new designs, all sizes of Osteoplug, Osteomesh and Osteostrip, and extended product shelf-life.*
- *Osteopore estimates that the serviceable available market value of the incremental access afforded by this extension exceeds A$115 million.*
- *This expanded approval means more patients will have access to the benefits of Osteopore's technology when undergoing cranial surgery.*

10 May 2021: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale, is pleased to announce that Osteopore has received notification of European Medical Devices Directive (MDD) certification for a significantly broader range of products. The CE Mark has been extended to include all Osteomesh, Osteoplug and Osteoplug-C sizes, as well as seven new shape variants.

The number of listed shape variants in Osteopore products has increased from 3 to 10, these additional designs allowing for access to an estimated 100,000 craniotomy cases per annum to bridge fresh craniotomy cuts created with associated surgical instruments, as well as to accommodate standard therapeutic devices.

The expansion in MDD certification means access to Osteopore products in Europe has grown from around 110,000 on-indication procedures to an estimated total of 210,000 cranial surgeries annually. Based on market research by CETAS Healthcare on annual cranial procedures, Osteopore estimates that the serviceable available market value of the incremental access afforded by the extension exceeds A$115 million. Germany and the UK account for just over 40% of the European market, which is expected to grow to 255,000 procedures per annum by 2025.

In addition, the shelf-life of Osteopore products has been extended from 2 years to 3 years. The longer shelf-life will improve the ability of distributors to carry more stock to support both high and low-volume hospitals.

Osteopore CEO Goh Khoon Seng remarked that the MDD approval of the expanded product range was an exciting day for both the Company and the field of regenerative medicine.

"Our products work with the body's natural regenerative capabilities rather than having to rely on artificial replacement parts. This expanded approval means more patients have access to the benefits of Osteopore's technology when undergoing cranial surgery."

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:
Carl Runde
Chief Financial Officer
Osteopore Limited
+61 4 0011 8017
carl_runde@osteopore.com

About Osteopore Limited

Osteopore Ltd, an Australian ASX listed company (OSX) with R&D and manufacturing in Singapore, is the global leader in the manufacture of innovative regenerative implants at commercial scale. By combining biomimetic tissue science with proprietary 3D printing and materials technology, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. These bioresorbable implants provide a scaffold for bone regeneration, dissolving predictably over time to leave only natural bone tissue. In collaboration with clinicians and researchers, Osteopore develops and manufactures implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs. For more information, visit us at www.osteopore.com.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.